DBVT News and Press, DBV Technologies S.A. From 02/20/24

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced...

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

2023-11-10 06:44:30 ET Summary DBV Technologies reports positive results for peanut allergy therapy in toddlers. Meta Platforms signs a deal with Tencent to sell a lower-priced version of its VR headset in China. BlackRock plans to create an Ethereum ETF, according to a filing...

2023-11-09 18:06:47 ET More on DBV Technologies DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript Equitable Holdings Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies ...

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy p...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010...

Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-al...

2023-10-31 21:57:09 ET DBV Technologies S.A. (DBVT) Q3 2023 Earnings Conference Call October 31, 2023 17:00 ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer ...

2023-10-31 16:35:20 ET More on DBV Technologies Equitable Holdings Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies For further de...

Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarif...